Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles

European Journal of Clinical Pharmacology

Volumn 41, Issue 3, 1991, Pages 263-265

  Hermann, L S ^a   Karlsson, J E ^b   Sjostrand A ^c  

^a LUND UNIVERSITY   (Sweden)

^b Jonkoping County Hospital   (Sweden)

^c Trans Hospital ^*  (Sweden)

Author keywords

adverse effects; C peptide; diabetes mellitus; Glibenclamide; lipoproteins; Metformin; NIDDM; serum lipids

Indexed keywords

CHOLESTEROL; GLIBENCLAMIDE; METFORMIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; BLOOD GLUCOSE; BODY WEIGHT; C-PEPTIDE; CHOLESTEROL; COMPARATIVE STUDY; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; FEMALE; GLYBURIDE; HUMAN; INSULIN; LIPIDS; LIPOPROTEINS; MALE; METFORMIN; MIDDLE AGE; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 0025873686     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/BF00315441     Document Type: Article

References (8)

1. Biguanides: Basic aspects and clinical uses
2. Lipids, diabetes and vascular disease: The time to act
3. Oral hypoglycaemic agents
4. A prospective study of the effect of 12 months treatment on serum lipids and apolipoproteins A-1 and B in type 2 (non-insulin-dependent) diabetes
5. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes
6. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects
7. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients
8. The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy